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Abstract
Latency-associated nuclear antigen (LANA) mediates c2-herpesvirus genome persistence and regulates transcription. We
describe the crystal structure of the murine gammaherpesvirus-68 LANA C-terminal domain at 2.2 A˚ resolution. The
structure reveals an alpha-beta fold that assembles as a dimer, reminiscent of Epstein-Barr virus EBNA1. A predicted DNA
binding surface is present and opposite this interface is a positive electrostatic patch. Targeted DNA recognition
substitutions eliminated DNA binding, while certain charged patch mutations reduced bromodomain protein, BRD4,
binding. Virus containing LANA abolished for DNA binding was incapable of viable latent infection in mice. Virus with
mutations at the charged patch periphery exhibited substantial deficiency in expansion of latent infection, while central
region substitutions had little effect. This deficiency was independent of BRD4. These results elucidate the LANA DNA
binding domain structure and reveal a unique charged region that exerts a critical role in viral latent infection, likely acting
through a host cell protein(s).
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Introduction
Herpesviruses are ubiquitous viruses, which infect many
mammalian species and are a leading cause of human viral
disease. There are two known human viruses from the gamma
herpesvirus sub-family. The Epstein-Barr virus (EBV), a gamma-1
herpesvirus (Lymphocryptovirus), and the Kaposi’s sarcoma-
associated herpesvirus (KSHV), a gamma-2 herpesvirus (Rhadi-
novirus). KSHV has an etiologic role in Kaposi’s Sarcoma, the
leading AIDS malignancy, as well as primary effusion lymphoma
and multicentric Castleman’s disease. EBV is also associated with
human cancers. These human viruses do not readily infect small
laboratory animals. The murine gammaherpesvirus 68 (MHV-68
or murid herpesvirus 4), a rhadinovirus that was isolated from
naturally infected rodents, is structurally and functionally related
to human gamma-herpesviruses and readily infects mice, thus
providing a mouse model for the investigation of gammaherpes-
virus pathogenesis [1–3].
A key feature of herpesvirus infection is their lifelong persistence
in the host in the form of latency. During latent infection, viral
genomes persist as multi-copy, circularized, extrachromosomal
episomes (plasmids). Only a small subset of viral genes is expressed
during latency. In the case of gamma-herpesvirus sub-family
members, latent infection is predominantly established in B
lymphocytes. Intransal infection of mice with MHV-68 causes
an acute self-limiting respiratory infection, followed by the
establishment of splenic latency, which peaks 14 days after
infection [4,5]. Splenic germinal centre (GC) B cells have a key
role both in the establishment and maintenance of viral latency
[6]. Like EBV [7], MHV-68 establishes latency predominantly in
activated germinal centre B cells. This strategy favours physiolog-
ical access of the virus to the memory B-cell pool, the major
reservoir of long-term latency.
KSHV latency-associated nuclear antigen (kLANA), a 1,162
amino acid protein encoded by ORF73 of the viral genome, is the
predominant gene expressed in latent infection. LANA mediates
persistence of episomal DNA and thus is required for long-term
maintenance of viral genomes in dividing cells, a role central to
viral latency. LANA promotes episomal replication and segrega-
tion to progeny nuclei after mitosis. The C-terminal region of
kLANA harbours a DNA-binding domain (DBD) that self-
associates and binds to terminal repeat (TR) DNA sequences of
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the viral episome [8–14]. LANA cooperatively binds to two sites
within the TR DNA, LBS1 and LBS2. LBS1 is a high affinity site
capable of facilitating the cooperative binding of LANA to LBS2.
Both sites contribute to the ability of LANA to suppress
transcription and to facilitate DNA replication [10]. An N-
terminal region of kLANA is able to attach to chromosomes
through binding to histones H2A and H2B [15]. Together, these
binding properties allow kLANA to tether the viral genome to
chromosomes during mitosis thus ensuring segregation of the
episome to daughter nuclei [16,17]. Association of viral genomes
with host mitotic chromosomes via a virus-encoded protein is a
strategy employed by a number of different latent DNA viruses.
Similar to the KSHV LANA, EBV EBNA1 and papillomavirus E2
proteins play a role in viral genome maintenance [18–22].
All gamma-2 herpesviruses encode homologs of KSHV LANA.
The ORF73 from MHV-68 encodes a much smaller, 314 amino
acid, 50 kDa nuclear protein (termed mLANA thereafter) which
lacks the extensive internal acidic and glutamine-rich repeat region
of kLANA. The C-terminal region of mLANA, comprising amino
acid residues 140 to 263, has amino acid similarity to the kLANA
DNA-binding domain. Similar to kLANA, mLANA was recently
shown to act on TR elements of the MHV-68 genome to mediate
episome maintenance and to associate with mitotic chromosomes
[23], and mLANA DNA-binding sites have been identified within
MHV-68 TR DNA [24]. In a mouse model of infection, latency-
associated nuclear antigen (LANA) protein is selectively expressed
in infected GC B cells [25]. Recombinant viruses that do not
express mLANA [26,27], or bear disruptive mutations in the
predicted DNA-binding domain fail to establish viable latency
[24]. mLANA therefore performs functions equivalent to those of
kLANA regarding episomal maintenance and is essential for
establishment of viable latency in vivo.
LANA proteins are also modulators of transcription from a
variety of cellular and viral promoters and affect cellular growth
[28,29]. Both kLANA and mLANA are able to regulate
transcription through E3-ubiquitin ligase activity [30–32].
mLANA promotes the polyubiquitination and subsequent protea-
somal-dependent nuclear degradation of host nuclear factor-kappa
B (NF-kB) [31]. The mechanism involves the assembly of an
Elongin C/Cullin5/SOCS (suppressors of cytokine signalling)-like
complex, mediated by an unconventional viral SOCS-box motif
(residues 199–206), homologous to the kLANA Cul5 box, present
in the C-terminal domain of mLANA [30,31]. Another motif also
within the C-terminal region of mLANA (QAKKLK motif,
residues 226–231) has been shown to bind to several members of
the BET (Bromodomain and Extra Terminal domain) family of
proteins, including BRD2, BRD3 and BRD4 [33,34], that interact
with acetylated histones. mLANA interaction with BET proteins
leads to activation of cell cycle promoters.
Secondary structure predictions have suggested that the C-
terminal regions of both mLANA and kLANA have similarity to
the X-ray structure of the DNA-binding domain of the EBV
nuclear antigen 1 protein (EBNA1) [35]. As a first step towards
understanding the mechanism by which the C-terminal region of
mLANA exerts its functions, we have determined the crystal
structure of this mLANA domain (amino acids 140–272).
mLANA140–272 forms a b-barrel induced dimer and has an overall
fold with an a-helix arrangement similar to that of the EBNA1 and
E2 latency protein structures [36,37]. However, the structure
reveals unique features that exert important effects on viral
persistence in an animal model.
Results
X-ray crystal structure of C-terminal mLANA reveals an
alpha+beta fold that assembles to form a dimer
The structure of the C-terminal domain of mLANA was
determined at 2.2 A˚ resolution. Data collection and refinement
statistics are reported in Table 1. The initial structure was solved
using the coordinates of the EBV EBNA1 dimer, which has both
functional and predicted secondary structure homology, as a
molecular replacement model [36]. The crystallized domain
contained residues 140–272, designated mLANA140–272 (Figure
S1). The refined electron density map was readily interpretable with
exceptions only at the termini and loop regions. The tertiary
structure of mLANA140–272 exhibits an a+b ferredoxin-like fold
(Figure 1A) which assembles to form a dimeric eight-stranded anti-
parallel b-barrel that is central to its functional architecture. This
dimer can be viewed from opposite sides of the b-barrel core which
for clarity is termed the ventral (top) and the dorsal sides (bottom)
(Figure 1B). Each monomer contributes an anti-parallel 4-stranded
b-sheet ‘‘half-barrel’’ from which helix a2 and a3 pack onto the
plaited sheet with their axis parallel to the strands of the sheet. The
core of the barrel is occupied by large hydrophobic surface (Figure
S2) that contributes to the stability of mLANA (Figure 1C). Size
exclusion analysis confirms that mLANA140–272 is also a dimer in
solution (Figure S2B and C). When the dimer interface was
disrupted by removal of residues 254–261, which lie below the b2–
b3 loop of the adjacent monomer, the melting temperature of
mLANA140–253 decreased drastically (Tm 43uC), indicating the
importance of these residues for stability (Figure 1D). The flanking
helix a1 caps this helical arrangement and lies perpendicular to the
central b-barrel. Helix a2, situated on the ventral side, is postulated
to be the DNA recognition helix (see below).
LANA cooperatively binds to two adjacent sites within TR
DNA, similar to the EBV DS element required for EBNA1
binding [38], suggesting a dimer-dimer interaction [39]. Analysis
of the mLANA crystal packing shows that dimers pack so that the
DNA-binding flanking helix a1 in each dimer is in position to
interact with both the flanking helix a1 and helix a3 from the
adjacent dimer (Figure 1E). Two phosphate ions on the ventral
surface contribute and coordinate the binding of the a1–a39
Author Summary
Herpesviruses establish life-long latent infections. During
latency, gammaherpesviruses, such as Kaposi’s sarcoma-
associated herpesvirus (KSHV), persist as multicopy, circu-
larized genomes in the cell nucleus and express a small
subset of viral genes. KSHV latency-associated nuclear
antigen (LANA) is the predominant gene expressed during
latent infection. C-terminal LANA binds KSHV terminal
repeat (TR) DNA to mediate DNA replication. TR DNA
binding also allows tethering of the viral genome to
mitotic chromosomes to mediate DNA segregation to
daughter nuclei. We describe here the crystal structure of
the murine gammaherpesvirus 68 LANA DNA binding
domain, which is homologous to that of KSHV LANA. The
structure revealed a dimer and we identified residues
involved in the interaction with viral DNA. Mutation of
these residues abolished DNA binding and viable latency
establishment in a mouse model of infection. We also
identified a positively charged patch on the dimer surface
opposite to the DNA binding region and found this patch
exerts an important role in the virus’s ability to expand
latent infection in vivo. This work elucidates the structure
of the LANA DNA binding domain and identifies a novel
surface feature that is critical for viral latent infection, likely
by acting through a host cell protein.
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dimer-dimer interactions and suggest at least 2 or 3 nucleotides
may span the spacer region between the LBS-1 and LBS-2 sites
(Figure 1F). Consistent with this finding, size exclusion chroma-
tography demonstrates that mLANA140–314 forms tetramers in
solution (Figure S2B). In addition, mLANA140–272 dimer forms a
tetramer to cooperatively bind adjacent mTR DNA binding sites
(described below).
Despite functional conservation, mLANA and EBNA1 proteins
do not exhibit amino acid similarity (Figure 2A). However, a
PHYRE2 program [40] search predicts mLANA secondary
structure homology between the C-terminal domains of mLANA
and EBNA1 (not shown), similar to other predictions [35]. A
superposition of both monomer structures is shown in Figure 2C.
Protruding perpendicular to the ventral face of mLANA lies a
partially disordered b2–b3 loop (199–215) (Figure 2B) that harbours
a motif required for the interaction of mLANA with Elongin B/C
(EloBC)-cullin-SOCS box (ECS)-type E3 ubiquitin ligase, resulting
in the polyubiquitination of NFkB [31]. Mutations at the base of this
loop (199VSCLPLVP206, underlined residues mutated to Alanine)
disrupt binding of mLANA to Elongin C and consequently
mLANA’s E3-ubiquitin ligase activity. A recombinant virus
containing these mutations fails to establish latency in vivo [31].
Ventral face of mLANA – phosphate binding traces the
site of DNA interaction
The structural basis for DNA recognition can be inferred from
the observed phosphate binding pattern. In total, seven phosphates
ions were located at the surface of mLANA. Five of these are
situated on the ventral face (Figure 2D–F) while the remaining two
cap the dorsal side of helix a1. Therefore, we consider the ventral
face as the putative DNA binding site of mLANA. We modelled
mLANA-DNA on the EBNA1-DNA structure (PDB ID: 1B3T)
and the mLANA structure accommodated the DNA well
(Figure 2G and Figure S3).
Mutation of predicted DNA phosphate contacts disrupts
DNA binding to TR DNA
To directly assess mLANA DNA binding, we used an
electrophoretic mobility shift assay (EMSA) to assess the ability
of mLANA to bind DNA. DNAse I footprinting analysis with
recombinant mLANA has shown three adjacent protected
regions within the mTR sequence [24], (Figure 3A, green and
blue regions). Two overlapping probes, mLBS1 or mLBS2,
each containing a portion of the protected sequence, or
control, overlapping adjacent sequence were used to assess
mLANA binding (Figure 3B). After incubation with mLANA, a
shifted complex was only observed after incubation with
mLBS1, and not with mLBS2 or control adjacent sequence
(Figure 3B). The mLBS1 complex was supershifted with anti-
FLAG antibody and was effectively competed with excess,
unlabelled mLBS1 or mLBS1-2 competitor (containing the
entire DNAse I protected region), but not unlabelled mLBS2
(Figure 3B). Despite the inability of mLANA to shift mLBS2
probe, size exclusion chromatography analysis demonstrated
that mLANA140–272 bound adjacent mLBS1 and mLBS2 sites
in mLBS1-2 oligonucleotide as a tetramer (Figure S6),
consistent with cooperative binding to both sites. Therefore,
similar to KSHV LANA DNA binding [10], mLANA
cooperatively binds to adjacent high and low affinity TR
DNA binding sites.
We then constructed mutations in the predicted mLANA
recognition helix intended to decrease interactions with its
cognate DNA. mLANA H186D/K187E contains substitutions
predicted to disrupt phosphate interactions and abolish DNA
binding, and this mutant was unable to complex with mLBS1
(Figure 3C). In contrast, mLANA K224A/K228A/K229A,
mLANA K224E/K228E/K229E, mLANA K251A/K253A,
and mLANA K251E/K253E, each contain substitutions within
a dorsal positively charged patch (discussed below) opposite the
predicted DNA interface, and each mLANA gel shifted the
mLBS1 probe (Figure 3C). The mLANA K251E/K253E
(Figure 3C, lane 7) complex was similar in intensity to that of
mLANA (Figure 3C, lane 3), though the intensities of the
mLANA K224A/K228/K229A and mLANA K251A/K253A
complexes were each reduced (Figure 3C, comparing lane 4 and
6 with lane 3). The reduced mLANA K224A/K228A/K229A
and mLANA K251A/K253A binding was likely in part due to
modestly lower protein expression (Figure 3D). Notably, mLANA
K224E/K228E/K229E demonstrated increased mLBS1 binding
(comparing lane 5 with lane 3). Therefore, as predicted by the
mLANA DNA binding domain structure, mLANA H186D/
K187E substitutions abolished DNA binding, but DNA binding
was preserved with dorsal mutations. The finding that dorsal
alanine substitutions of lysine reduced DNA binding, while
glutamate substitutions did not, suggests that substituting non
charged residues may have subtle effects on DNA binding
domain folding.
We characterised mLANA TR DNA binding by surface
plasmon resonance (SPR) and isothermal titration calorimetry
(ITC) to determine the dissociation constant (KD) for mLBS1.
The KD for wild type and H186D/K187E were determined by
Table 1. Data collection and refinement statistics.
X-ray diffraction data
Wavelength (A˚) 1.129
Space group C2
Cell dimensions: a, b, c (A˚) 88.6 61.7 63.7
a, b, c (u) 90.0, 99.4, 90.0
Resolution (A˚) 37.6–2.2 (2.32–2.20)
Rmerge 0.059 (0.64)
Rmeas/Rpim 0.063 (0.69)/0.023 (0.25)
I/sI 21.4 (3.3)
Completeness (%) 99.9 (98.5)
Redundancy 7.5 (7.4)
Total measured reflections 130,451
Unique reflections 17,333 (2,507)
Wilson B-factor (A˚2) 42.3
Refinement
Resolution (A˚) 30.8–2.2
Rwork/Rfree 0.1714/0.2032
Atoms: protein (chain A)/protein
(chain B)/PO422/water
1979/1946/35/62
B factors: chain A/chain B/PO4/water 49.4/50.7/51.8/41.9
Rmsd bond length (A˚) 0.007
Rmsd bond angles (u) 1.168
Ramachandran analysis:
favoured/allowed (%)
93.0/7.0
Rwork and Rfree are defined by R=ghklIFobs|2|FcalcI/ghkl|Fobs|, where hkl are
the indices of the reflections (used in refinement for Rwork; 5%, not used in
refinement, for Rfree), and Fobs and Fcalc are the structure factors deduced from
measured intensities and calculated from the model, respectively. Values in
parentheses are for the highest resolution shell.
doi:10.1371/journal.ppat.1003673.t001
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Figure 1. Structure of the C-terminal domain of mLANA. (A) A ribbon representation with secondary structure assignment for a monomer of
the MHV-68 mLANA140–272 DNA-binding domain (see also Figure S1). (B) A representation of the mLANA140–272 quaternary structure and its dimeric
conformation viewed along the non-crystallographic axis and illustrates the a-helical arrangement around the b-barrel core. The two chains are
coloured in blue (chain A) and green (chain B). (C) Cross section of the dimer interface with coloured surface properties. A large area (,1440 A˚2)
constituting the hydrophobic core is displayed in yellow with the hydrogen bonding residues displayed in blue. Deleting residues P254–P259 in red
Crystal Structure of mLANA DBD
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titrating mLANA124–272 against immobilized mLBS1 (Figure 3E
and F). The KD’s were 169 nM and 960 nM for wild type and
mLANA H186D/K187E, respectively (Table 2). Thermodynam-
ics binding parameters in solution measured by ITC using the
more soluble mLANA124–314 fitted well to a one-site model,
indicating one distinct mLANA binding site (Figure 3G), and
provided a calculated KD of 66 nM (Table 3). The discrepancy
between the SPR and ITC dissociation constants was due to the
inaccessibility of more than 50 percent of mLANA124–314 for
DNA binding as observed from the calculated N value from ITC
(0.2760.03 dimer per TR-DNA)(Supporting Information, Text
S1).
mLANA exhibits a novel positive patch on the dorsal face
and interacts with BRD4
Electrostatic surface analysis of the mLANA protein reveals an
extensive positive patch on the dorsal side which includes residues
Arg-156, Lys-224, 225, 228, 229, 231, 251, 253, and Arg-232
(Figure 4A and B and S5B). Both Arg-156 and Lys-229 interact
with a phosphate ion which is located on the dorsal face of helix
a1. Lys-251 and 253 lie on the 2-fold non-crystallographic
symmetry axis of the dimer interface (Figure 4B). The positive
electrostatic surface also encompasses the identified
226QAKKLK231 motif that is involved in binding to BET proteins
[34]. Both mLANA and kLANA have been described to bind to
the ET domain of BET proteins and the cluster of positive charges
is energetically organized to establish charge-charge interactions
with a negatively charged patch on the helical ET domain of the
BET proteins BRD2 and BRD4. Four key Lysine residues are
conserved in both mLANA (Lys-228, Lys-229, Lys-251, and Lys-
253) and kLANA (Lys-1113, Lys-1114, Lys-1138 and Lys-1140)
(Figure 2A).
Although mLANA was previously described to bind BRD4, a
complete mapping of mLANA binding within BRD4 had not been
performed. Therefore, we investigated mLANA binding to BRD4
(Figure 4C). GST mLANA 1–168 or GST mLANA 140–314 were
used to assess binding to in vitro translated BRD4 or fragments
spanning full length BRD4. GST mLANA140–314 precipitated full
length BRD4 more efficiently than did GST mLANA1–168
(Figure 4D). Interestingly GST LANA mLANA1–168 bound
BRD4 at two sites, BRD4 1–470 and BRD4 1047–1362, while
GST mLANA 140–314 bound BRD4 471–730 (Figure 4D). Since
BRD4 471–730 contains the conserved ET domain in its C-
terminal portion, we then assessed binding of mLANA to GST
BRD4 471–594 (upstream of the ET domain) or GST BRD4 595–
730 (ET domain and SEED motif). mLANA bound BRD4 471–
594, upstream of the ET domain while consistent with previous
results [41], kLANA bound the ET domain containing region in
BRD4 595–730 (Figure 4E).
Since mLANA residues 226–231 were previously shown to be
important for BRD4 binding [34], and since C-terminal mLANA
bound the region upstream of the ET domain, we assessed the
ability of mLANA, or mLANA mutated at positively charged
residues, including within 226–331, to bind BRD4 471–594.
mLANA K251E/K253E and mLANA K251A/K253A contain
either negatively charged or neutral substitutions at residues in the
central positive patch region, while mLANA K224E/K228E/
K229E and mLANA K224A/K228A/K229A contain similar
substitutions at the periphery of the positive patch. mLANA and
each of the mutants bound BRD4 471–594 (Figure 4F). However,
BRD4 binding was substantially reduced for mLANA K251E/
K253E and modestly reduced for mLANA K224E/K228E/
K229E (Figure 4F). In addition, we assessed the ability of GST
mLANA 124–272, GST mLANA 124–272 mutated at dorsal
positively charged residues, or GST mLANA 124–272 H186D/
K187E, which is abolished for DNA binding (Figure 3), for the
ability to bind BRD4 or fragments spanning BRD4. GST mLANA
124–272 bound BRD4 and BRD4 471–730 (Figure 4G), similar to
GST mLANA 140–314 (Figure. 4D). Each of the mLANA
mutants also bound both BRD4 and BRD4 471–730, although
binding was reduced for mLANA 124–272 H186D/K187E,
mLANA K224E/K228E/K229E, and mLANA K251E/K253E
(Figure 4G). The finding that mLANA 124–272 H186D/K187E
had reduced BRD4 binding suggests a potential role for these
residues in interacting with Brd4. Therefore, substitution of
negatively charged, but not neutral, residues for positively charged
amino acids on the dorsal positive patch of C-terminal mLANA
reduces BRD4 binding.
Loss of DNA binding abolishes virus persistence in mice
We assessed the role of mLANA binding to viral DNA on virus
persistence in mice. A recombinant virus was generated bearing
the mLANA H186D/K187E mutations in the predicted mLANA
DNA recognition helix (designated vmLANAH186D/K187E;
Figure 5A). We first compared the kinetics of lytic viral replication
in vitro and during the acute phase of infection in lungs. Lytic
replication kinetics was essentially preserved, though changes in
the pattern of lytic infection could be identified (Figure 5B and C;
Supporting Information, Text S1). This result is consistent with
mLANA having a predominant role in latency. We next
proceeded to investigate the impact of the introduced mutations
in the ability of MHV-68 to expand latent infection in GC B cells
and establish persistent infection in mice. vmLANAH186D/K187E
showed a marked defect in in vitro reactivation from latency
(Figure 5D), and viable virus was barely detectable beyond the
limit of detection of the assay as early as 14 dpi. This viral mutant
also showed a clear defect in the frequency of viral-DNA positive
splenocytes (Figure 5E and Table 4). Consistent with this deficit,
the frequency of vmLANAH186D/K187E infection in GC B cells at
the peak of virus latency (14 dpi) was three orders of magnitude
lower (Figure 5F and Table 4). This result was confirmed by
visualisation of latently infected cells within GCs in splenic sections
(Figure 5G, a–b). Notably, analysis of vmLANAH186D/K187E at 21
and 50 dpi showed that loss of mLANA DNA binding severely
diminished virus persistence in mice (Figure 5D and E). These
results demonstrate that mLANA binding to its cognate DNA is
essential for the expansion of latent infection in GC B cells and is
critical for virus persistence.
from the C-terminus destabilizes the dimer, as it contributes to the hydrophobic stability of the dimer interface (see also Figure S2). (D) Fluorescence-
based thermal shift analysis of mLANA truncations (arrows display the midpoint of the unfolding transitions). The midpoint melting temperatures of
the protein-unfolding transition (Tm) for mLANA DBD truncations are shown for the optimal buffers. (E) mLANA tetramer assembly presumed for
cooperative TR DNA binding as observed in the crystal packing with the symmetry equivalent dimer. Phosphate interactions coordinate the dimer-
dimer interface. Two dimers form a tetramer stabilized by an interface with a surface area (,535 A˚2) per monomer that is approximately 12% of that
of the total surface of a single subunit (,7,500 A˚2). (F) A ribbon representation of the dimer-dimer interface view from the ventral side. In the
interface Arg-148 from dimer-2 stacks against Tyr-241, and makes a weak hydrogen bond with Tyr-237 from dimer-1. The arginine residue is
conserved in both mLANA and kLANA proteins which has the ability to intercalate between hydrophobic aromatic amino acids on the second dimer.
doi:10.1371/journal.ppat.1003673.g001
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Electrostatic surface residues on the dorsal face exert a
role in expansion of latent infection in GC B cells
We investigated the role of the positive electrostatic surface
residues on the pathogenesis of MHV-68 infection taking into
account their charge and relative position on the dorsal face.
Recombinant viruses were engineered to contain neutral or
negatively charged mutations at the centre or periphery of the
positive patch (Figure 5A). This set of mutations did not affect viral
replication in vitro or affect lytic infection in lungs of mice
(Figure 5B and C). However, when the latent phase of the
infection was analysed a clear phenotype could be ascribed to
mutations located at the periphery of the positively charged dorsal
motif. Whereas vmLANAK251A/K253A and vmLANAK251E/K253E
showed levels of latency comparable to wild type virus (Figure 5D,
F and Table 4), viruses vmLANAK224A/K228A/K229A and vmLA-
NAK224E/K228E/K229E showed a significant (p,0.0001) latency
deficit at 14 dpi (Figure 5D). This deficit was confirmed by
quantification of the frequency of viral DNA-positive cells in total
splenocytes (Figure 5F and Table 4). This phenotype is unlikely to
reflect inadvertant mutations introduced during the mutagenesis
process since the equivalent phenotype was observed in both
independently derived mutant viruses. Moreover, revertant viruses
in which the mutated K224/K228/K229 residues were restored
to wild type status did not show any defects in latent infection
(Figure 5E), demonstrating that phenotypic changes observed were
intrinsic to this locus and not a consequence of mutations
elsewhere in the viral genome. Quantification of the frequency
of infection in purified GC B cells (Figure 5G and Table 4) and
visualisation of latently infected cells by in situ hybridisation
(Figure 5H, c–d) revealed that replacing a positively charged lysine
for the oppositely charged glutamate accentuated the attenuated
phenotype when compared to replacement with a non-polar
alanine. Notably, the attenuated latency phenotype ascribed to
Lys-224, 228, 229 did not correlate with the activity of mLANA to
bind BRD4. That conclusion is based on the result that BRD4
binding was reduced for mLANA K251E/K253E (Figure 4F and
4G), however vmLANAK251E/K253E showed no latent infection
phenotype (Figure 5D, F, G and H, e–f). Further, mLANA
K224A/K228A/K229A bound BRD4 normally (Figure 4F and
4G), yet vmLANAK224A/K228A/K229A was deficient for latent
infection. Taken together these data demonstrate that Lys residues
224, 228 and 229 located at the periphery of the positively charged
dorsal motif are required for the efficient expansion of infected GC
B cells, likely acting through a host cell protein other than BRD4.
Discussion
C-terminal LANA is the most highly conserved LANA domain,
and its ability to bind DNA is essential for viral DNA replication
and episome persistence [12]. Here, we solve the X-ray crystal
structure of the mLANA DNA binding domain. The overall fold
comprises a rigid and thermostable b-barrel dimer flanked on
either side by an a-helix arrangement. The structural features of
mLANA are common to EBV EBNA1 and HPV E2 proteins,
indicative of their conserved biological functions in episome
maintenance and transcriptional activation.
This work identifies ventral C-terminal mLANA as the DNA
binding interface and demonstrates its essential role in latent viral
infection. The similarity in the protein folds of mLANA with
EBNA1, the sites of mLANA phosphate ion binding, and the
modelled superposition of the EBNA1-DNA complex all support
that the ventral side interfaces with DNA. Furthermore, a high
affinity TR DNA LANA binding site (mLBS1) was demonstrated
by EMSA and shown by ITC to bind mLBS1 with nanomolar
affinity, 66 nM, with enthalpy as the major driving force for
binding. Similar to kLANA, mLANA cooperatively binds adjacent
high and low affinity TR DNA binding sites. Disruption of
targeted residues on the ventral surface abolished DNA binding
(Figure 3), providing direct evidence that this surface is the DNA
binding interface. Moreover, engineering the same disruptive
mutations into the genome of MHV-68 abolished the ability of the
virus to expand latent infection in GC B cells and eliminated
persistence of virus that was capable of reactivation. This result
was consistent with recent findings that virus containing mLANA
incapable of binding DNA was highly deficient for virus ex vivo
reactivation from splenocytes [24]. This work establishes that
LANA binding to TR DNA is critical for viral persistence in
proliferating GC B cells. Most importantly, it supports a model in
which a strategy of expansion of virus infection in GC B cells to
access persistence in long-lived memory B cells is vital for host
colonisation. This establishes a parallel with EBV where the same
strategy for virus persistence has been proposed based upon
clinical investigation [7].
Prior genetic and functional analyses of the LANA DBD can
now be interpreted in light of the solved mLANA structure.
Consistent with their predicted contacts with DNA, mutations
within a helices 1 and 2 affect DNA binding. mLANA Pro179Thr
or Leu150Pro resulted in loss of the ability of mLANA to protect
its binding site from DNase I cleavage [24,39,42]. Pro-179 is found
Figure 2. Conserved sequence and structural features of mLANA. (A) Structure based sequence alignment of the MHV-68 mLANA DBD with
the DBD domains of KSHV kLANA, EBV EBNA1 (PDB ID: 1VHI), and EBNA1 DNA complex (PDB ID: 1B3T). The secondary structure of mLANA DBD is
shown above the alignment while the secondary structure elements of EBNA1 structure are labelled below (blue). The recognition helix a2 is coloured
in green with key residues highlighted. The recognition helix residues His-186 and Lys-187 are marked in yellow. Green stars indicate the residues of the
recognition helix that interacted with phosphate ions. Conserved dorsal residues with positive charge are indicated by blue triangles. Figure is made
with ESPript (http://espript.ibcp.fr/ESPript/ESPript/) Key: Red boxes and white characters indicate strict identity, red characters indicate similarity in a
group and blue frames indicate similarity across groups. (B) Representation of the dimer interface on the ventral side highlighting the conformation of
the b2–b3 SOCS box loop. The b2–b3 loop is the proposed hydrophobic interface for Elongin C interaction and shows the accessibility of residues Cys-
201 and Leu-204 of the 199VSCLPLVP206 SOCS motif, shown as sticks. The interface highlights the conserved hydrogen bond between chain A Tyr-216
(blue) and chain B Tyr-216 (green) and shows the Pro-198 b-bulge. (C) Structural superposition of mLANA140–272 (chain B), in pink, with EBNA1 (PDB ID
1vhi; chain B), in blue (r.m.s deviation= 1.37 A˚ based on 82 equivalent Ca atoms). The recognition helix a2 in mLANA is shorter when compared to
EBNA1 by 4 amino acids (1 helical turn), this has implications for both DNA binding and specificity. (D) mLANA dimer showing the electrostatic surface
of the ventral side, the proposed DNA binding site and highlights five of the phosphate binding sites that trace DNA interactions. Electrostatic surface
of mLANA was calculated and displayed using CCP4mg. The surface potentials displayed scale from 20.5 V (red, negatively charged) to +0.5 V (blue,
positively charged). (E) A ribbon representation of the dimer in the same orientation, showing the secondary structure arrangement. (F)
Representation of the recognition helix a2 and the key residues which interacts with 3 different phosphates through the side-chains of residues His-
178, Thr-181, Asn-183, Lys-184 and Lys-187. (G) Structural model of a mLANA DBD DNA complex (rotated relative to panel E) using mLBS1 DNA docked
onto the 18 bp EBNA1 DNA recognition sequence followed by energy minimisation using YASARA. The DNA shown was that which gave the best
minimized score as indicated in Figure S3. In the structure each nucleotide is drawn in a different colour for clarity, adenine (red), guanine (green),
cytosine (lightorange), and thymine (lightblue). The arrow indicates specific nucleotide interactions at sequence 16 and 17 of the modelled TR DNA.
doi:10.1371/journal.ppat.1003673.g002
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Figure 3. mLANA binds TR DNA with nanomolar affinity. (A) MHV-68 TR sequence with genomic coordinates is shown. Oligonucleotide
sequences used for gel shift analyses are boxed. Sequence protected by DNAse I footprint analysis [24] is shown in blue and green. (B) mLBS1, mLBS2
or control adjacent 32P-labeled oligonucleotides were each incubated with in vitro-translated mLANAc3F wt or control reticulocyte lysate (control ivt).
Anti-FLAG antibody, or 50 fold excess unlabeled (cold) competitor were included in incubations where indicated. FLAG antibody supershifted
complex is indicated by an asterisk. (C) mLBS1 32P-labeled oligonucleotide was incubated alone (lane 1), with control reticulocyte lysate (lane 2;
control ivt), or the indicated in vitro-translated mLANA proteins. O, gel origin; P, free probe. (D) Western Blot is shown containing the same in vitro-
translated mLANA proteins as in (C). (E and F) Panels show the SPR difference sensorgram with increasing concentrations of protein. Protein
concentrations injected are as labelled. A 3-min association was followed by a 3-min dissociation phase. The bottom panels represent the KD
determination. The binding constant obtained by Langmuir fit of wild-type and mutant data sets using a 1:1 stoichiometry-binding model. (G) ITC
binding profile of mLANA124–314 with mLBS1 at 25uC. Top panel show raw differential power signals recorded versus time for 30 mM of mLBS1
titrations injected into a cell containing 8.5 mM of mLANA124–314 dimer. Bottom panel show integrated injection heats versus the molar ratio of
mLANA to mLBS1. Kinetic parameters obtained from the experiments are given in Table 3.
doi:10.1371/journal.ppat.1003673.g003
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at the N-terminus turn of the a2-helix, and restricts the dihedral
angles of the preceding amino acid His-178, diminishing the
flexibility of His-178, a residue expected to be important for DNA
interaction (Figure 2F). The Leu150Pro substitution in helix a1
causes helix disruption as proline is expected to destabilize the a-
helix structure, causing a kink. Multiple mutations within a helices
1 and 2 of the kLANA DBD also disrupted DNA binding
[24,39,42]. As some kLANA mutations located in regions other
than a helix 1 and 2 also disrupted binding, it is likely that these
disturb secondary structure and folding of the DBD. Consistent
with the large surface area interface of the dimer, only larger
deletions of ,10–15 amino acids were able to disrupt kLANA self-
association [12,39,43].
Inhibition of NF-kB signalling is essential for MHV-68 latency
[31]. mLANA recruits EC5S E3 ubiquitin ligase complex to target
NFkB for degradation by the ubiquitin-proteasome pathway by
way of an unconventional SOCS box motif (199VSCLPLVP206).
SOCS box containing proteins mediate interactions with elongins
B and C to target substrates for degradation. The mLANA
structure shows that this motif forms a loop perpendicular to the
DNA binding interface, likely allowing accessibility for elongin
binding without disrupting DNA binding. A strictly conserved
leucine residue [44,45] is part of an essential hydrophobic
interface required for Elongin C binding. This feature may be
fulfilled by residues Leu-202, Pro-203 and/or Leu-204 that are
positioned on the b2–b3 loop to accommodate an ElonginBC-
Cul5 complex. A conserved cysteine is critical for SOCS-box
interaction with Elongin C [44], and the LANA SOCS-box motif
includes Cys-201 conserved in both mLANA and kLANA. The
mLANA SOCS loop is an atypical structural motif since a typical
SOCS-Elongin C interaction forms a ‘‘folded-leaf’’ four helix
cluster. Since LANA does not display a standard SOCS box
consensus sequence, it is likely that LANA has acquired a unique
strategy to recruit an EC5S ubiquitin ligase complex.
The most striking feature in the mLANA structure is the
positive electrostatic charge on the dorsal face, which is absent in
EBNA1 and E2. Residues 226QAKKLK231, within this charged
region, were previously identified as binding the BET family of
proteins, BRD2 and BRD4 by using BRD4 as a probe against an
mLANA peptide array and these findings were confirmed in co-
immunoprecipitation experiments with mLANA mutated at these
residues [34]. Consistent with these results, we found that
substitution of positively charged for negative residues in mLANA
K224E/K228E/K229E reduced BRD4 binding, although sub-
stitution with neutral residues in mLANA K224A/K228A/
K229A did not. Similarly, mLANA K251E/K253E, but not
mLANA K251A/K251A, was reduced for BRD4 binding. These
findings suggest possible electrostatic inhibition when positively
charged residues were substituted for ones with a negative charge.
Our results differ from other work [34] since the region
immediately upstream of the BRD4 ET domain, rather than
the ET domain itself, mediated C-terminal mLANA binding.
Interestingly, in contrast to mLANA, and as previously reported
[41], kLANA bound the ET domain rather than the upstream
BRD4 region, suggesting independent evolution of this LANA
binding. We also found that N-terminal mLANA binds to distinct
BRD4 regions compared to C-terminal mLANA, although the C-
terminal domain has the more prominent role in BRD4 binding
(Figure 4). Interestingly EBNA1 and E2 each bind BRD4 through
non C-terminal regions. EBNA1 binds BRD4 through N-
terminal residues 61–83 [46], while the N-terminal E2 transacti-
vation domain binds BRD2/4 [47]. Most importantly, our mouse
infections with mutated viruses showed that this novel electro-
static charge patch on the mLANA dorsal face is required for
efficient expansion of latently infected GC B cells. The charged
patch could be divided into two components with different
functional effects, consisting of a central region and a peripheral
region. Unexpectedly, the attenuated latency phenotype ascribed
to mutations in Lys-224, 228, 229 could not be attributed to
BRD4. This finding suggests that this region is likely to be acting
through a host cell protein other than BRD4, possibly a different
BET protein.
The resolution of the crystal structure of the DBD of mLANA
provides advantages for pathogenesis studies in a mouse model. In
this study, solving the mLANA DBD structure enabled the rational
design of mutations in the DNA binding interface that resulted in
loss of DNA binding and eliminated virus associated GC cell
proliferation and persistence of viable virus in the host. In
addition, the mLANA quaternary structure revealed a novel
structural motif composed of a patch of positively charged lysine
residues on the dorsal face. Results showed that this feature exerts
a key role in the expansion of latently infected GC B cells. Thus,
combining structural, in vitro and cellular studies with an animal
model of infection offers a unique opportunity to investigate viral
pathogenesis.
Materials and Methods
Ethics statement
This study was carried out in strict accordance with the
recommendations of the Portuguese official Veterinary Directorate
(Portaria 1005/92). The Portuguese Experiments on Animal Act
strictly comply with the European Guideline 86/609/EEC and
follow the FELASA. Animal experiments were approved by the
Portuguese official veterinary department for welfare licensing
under the protocol number AEC_2010_017_PS_Rdt_General
and the IMM Animal Ethics Committee.
Cloning, expression and purification of mLANA
A series of C-terminal truncations of mLANA DBD were cloned
into the pET-49b vector (Novagen) and the proteins expressed
with an N-terminal GST-His-tag (Figure S1) in Escherichia coli
BL21 Star (DE3) cells (Invitrogen) containing the pRARE2
plasmid (Novagen). Proteins were purified on an A¨KTA Explorer
(GE Healthcare) FPLC system. Point mutations within mLANA
Table 2. Interaction of mLANA124–272 and mLANA124–272
H186D/K187E with TR-DNA.
KD WT Mut H186D/K187E
EMSA* Binding No binding
SPR 169 nM 960 nM
ITC 66612 nM ND
*Full-length mLANA protein used in this experiment.
doi:10.1371/journal.ppat.1003673.t002
Table 3. Kinetic values for mLANA124–314 with TR-DNA by ITC.
DH0 kJ/mol 2DTS0 kJ/mol DG0 kJ/mol KD nM n
WT 2103.963.4 63.063.4 241.060.5 66612 0.2760.03
Standard deviations were calculated from three independent measurements.
Gibbs free energy and entropy were calculated using these equations DG=RT
lnKD and DG=DH2TDS.
doi:10.1371/journal.ppat.1003673.t003
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were engineered using the QuikChange multisite-directed muta-
genesis kit (Stratagene). Truncations of mLANA (Figure S1A) were
PCR cloned into pET-49b as BamHI-NotI fragments using the
appropriate primers (Figure S1B). All constructs were confirmed
by DNA sequencing. The vector carries an N-terminal GST-tag
and His-tag coding sequences followed by a recognition site for the
human rhinovirus (HRV) 3C protease (LEVLFQ/GP). Cultures of
BL21 Star (DE3) cells transformed with mLANA plasmids were
grown until the mid-log phase (A600 nm = 1.8) in Terrific Broth
medium supplemented with kanamycin (50 mg/ml) and chloram-
phenicol (30 mg/ml), induced with 0.5 mM isopropyl-1-thio-b-D-
galactopyranoside, and grown for an additional 16 h at 18uC.
Cells were harvested by centrifugation, resuspended in a buffer
containing 50 mM Na/K phosphate (pH 7.0), 500 mM NaCl,
1 mM Tris (2-carboxyethyl) phosphine (TCEP), 10 mM imidaz-
ole, EDTA-free protease inhibitor cocktail (Roche) and 5 mg/ml
OmniCleave, (Epicentre), and stored at 280uC. The cell pellet
was disrupted using an APV-2000 continuous homogenizer (APV,
Madrid, Spain) at 6000 psi. After centrifugation, the supernatant
was loaded onto a HisTrap HP (GE Healthcare) column, pre-
equilibrated in 50 mM Na/K phosphate (pH 7.0), 500 mM NaCl,
1 mM TCEP, 10 mM imidazole, and proteins eluted with a linear
gradient from 10–500 mM imidazole in the same buffer using a
A¨KTA Explorer (GE Healthcare) FPLC system (Figure S1C). The
GST-Histidine tag was removed by overnight incubation with 3C
protease at 4uC and the cleaved protein passed over a GSTPrep
FF (GE Healthcare) column (to remove any uncleaved protein as
well as the GST-tagged 3C protease) connected end to end to a
HiPrep Heparin FF (GE Healthcare) column. The columns were
disconnected and the heparin bound mLANA proteins eluted with
a linear gradient from 0.3–2 M NaCl. Following 3C cleavage the
recombinant protein contained the vector-derived sequence
GPGYQKDP at the NH2-terminus. Finally, the protein was
applied to a Superdex S75 16/60 filtration column (GE
Healthcare) in 10 mM MES buffer, pH 6.5, 300 mM NaCl and
1 mM TCEP and stored at 280uC.
Differential scanning fluorimetry
Assays were performed on an iCycle IQ5 Real Time PCR
Detection System (BioRad) with excitation and emission wave-
lengths of 490 and 575 nm, respectively. Reaction volumes of
20 ml contained 1 mg of protein and 106 of SYPRO orange
(Invitrogen) previously diluted in 20 mM HEPES pH 7.5 from an
initial 50006 stock. The reaction mix was prepared by adding
2.0 ml of protein-dye mixture solution to 18.0 ml of each buffer
from the JBS Solubility kit (Jena Biosciences). For the thermal
denaturation the plates were heated at a rate of 1uC/min from 20
to 90uC with a 10 s hold step for every point and fluorescence was
measured in 1uC increments. Experiments were carried out in
duplicate, and Tm values were calculated for each well using
nonlinear regression analysis in the curve-fitting program
GraphPad Prism. The Tm values were incorporated into a
Microsoft Excel script (ftp://ftp.sgc.ox.ac.uk/pub/biophysics) for
comparison of melting curves and thermal shifts.
Crystallization and structure determination
Screening of crystallization conditions was performed using four
sparse matrix formulations from commercial screens (Structure
Screen I+II, PACT-premier, JCSG-plus and Stura Footprint
combination from Molecular Dimensions, UK) in round-bottom
Greiner 96-well CrystalQuick plates (Greiner Bio-One) and
performed using a Cartesian Crystallization Robot Dispensing
System (Genomics Solutions). The sitting-drop vapour-diffusion
method was used, with 100 nl protein sample (30 mg/ml) mixed
with an equal volume of the reservoir screening solution. In less
than 1 day at 21uC, mLANA140–261 crystallized as small needle
shaped crystals in condition E10 (0.1 M Tris-HCl pH 8.5, 20% w/
v PEG 2000 MME, 0.01 M nickel chloride) of the Structure
Screen and truncation mLANA140–272 crystallized as thin, but
large, plate-like crystals in condition F10 (0.1 M Tris-HCl pH 8.5,
25% w/v PEG 3350, 0.2 M lithium sulphate) of the Stura
Footprint Combination Screen.
While crystal optimization by sitting-drop vapour diffusion
technique failed for mLANA140–261. Diffraction-quality crystals for
mLANA140–272 were obtained by exchanging the protein buffer to
the optimal buffer system suggested by DSF assays (50 mM Na/
K phosphate pH 7.0). mLANA140–272 crystals were further
optimized by serial streak-seeding in decreasing precipitant
concentrations, with optimal growth to 0.0560.0560.15 mm in
drops formed by mixing an equal volume of the protein solution
with a reservoir solution that contained 0.1 M Na/K phosphate
pH 7.0, 0.1 M lithium sulphate, 22% w/v PEG 3350 and 4% v/v
1,4 dioxane. Crystals were transferred to mother liquor supple-
mented with 20% v/v glycerol, and cryocooled in liquid nitrogen.
A diffraction data set was collected from EMBL beamline P14
at PETRA III (DESY, Germany), indexed and integrated with
XDS [48], then merged and converted with Pointless [49] to mtz
format for scaling in SCALA [49]. The structure was solved by
molecular replacement using Phaser [50] with the EBNA1 dimer
(PDB ID: 1VHI) as a search model. An initial model of the
structure was autobuilt in PHENIX [51] with manual rebuilding
of the model performed in Coot [52] and refined in PHENIX.
The crystallographic data are summarized in Table 1. The
structure was validated using MOLPROBITY [53] as implement-
ed in PHENIX. The analysis of the dimer interface used the
Protein interfaces, surfaces and assemblies service PISA at
European Bioinformatics Institute [54]. Energy minimization for
3D structures of mLANA-DNA models was performed using
YASARA [55]. Structural illustrations were prepared with
PyMOL [56] and CCP4MG [57].
Figure 4. The dorsal face of mLANA and its role in BRD4 binding. (A) Electrostatic surface showing the residues that contribute to the
positive electrostatic potential, Arg-156, Lys-224, 225, 228, 229, 231, and Arg-232, which run along the spine of the dorsal face. The QAKKLK motif is
highlighted. The scale is from20.5 V (red, negatively charged) to +0.5 V (blue, positively charged). (B) Ribbon diagram highlighting the key positively
charged residues. (C) Schematic diagram of BRD4 and fragments used for mapping the mLANA binding. BD, bromodomain; ET, extra-terminal
domain; SEED, conserved region consists of polyserine (S) residues interspersed with glutamic (E) and aspartic (D) acid residues [62,63]. (D) BRD4
fragments were labelled with [35S]-methionine and assayed for binding to GST mLANA 1–168 or GST mLANA 140–314. Ponceau S detection of
proteins (lower panel) is shown and full length GST, GST mLANA 1–168, or GST mLANA 140–314 are indicated with asterisks. (E) Western blots for
mLANA and kLANA are shown in the upper panel; the Ponceau S stained GST and GST fusion proteins are displayed in the lower panel. Despite the
lower intensity of the GST and GST BRD4 595–730 bands after Ponceau S staining, Coomassie blue staining (Figure S4) showed that similar amounts
of fusion proteins were present. (F) After incubation with GST or GST BRD4 471–594, bound mLANA was detected by FLAG immunoblot. Ponceau S
staining of fusion proteins is shown. (G) BRD4 or BRD4 fragments labelled with [35S]-methionine were assayed for binding to GST mLANA 124–272 or
GST mLANA 124–272 containing substitution mutations. Coomassie blue staining of fusion proteins is shown in the bottom panel.
doi:10.1371/journal.ppat.1003673.g004
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Electrophoretic mobility shift assays
mLANA WT and mutants were in vitro-translated using TNT
coupled Reticulocyte Systems (Promega # L4610) from pBS-
mLANAc3F WT (Figure 3B), pBS mLANA H186D/K187E, pBS
myc mLANAc3F wt (Figure 3C) and pBS mLANA K224A/
K228/K229A, pBS mLANA K224E/K228/K229E, pBS
mLANA K251A/K253A, or pBS mLANA K251E/K253E.
mLBS probes were 32P-labeled using Prime-It II (Agilent
technology #300385). EMSAs were performed using 20,000
(panel B) or 30,000 (Figure 3C) cpm 32P-labeled mLBS1, mLBS2,
or control adjacent sequence, each also containing a GATC 59
overhang. Probes were incubated 20 min. at RT with 5 to 10 mL
of in vitro translated mLANA in EMSA buffer (20 mM Tris-HCl
pH 7.5, 50 mM KCl, 10 mM MgCl2, 1 mM EDTA, 20 mg/mL
polydI-dC [Amersham Bioscience #27-7880-02], 0.1 mM DTT
and 10% glycerol). For competition controls, 50 fold excess
unlabeled mLBS1, mLBS2, or mLBS1-2 were included in the
incubation. To generate mLBS1-2 oligonucleotide, TATAATG-
GATCCggcgccatgcgcccgcgcctggggcgccacgcggcg and TTATATG-
GATccccgggtctccagggcgcgc-cgcgtggcgccccag primers were an-
nealed and extended using Prime-It II kit (capital letters indicate
additional non TR sequence). The resulting oligonucleotide was
ligated into the EcoRV site of pBluescript. mLBS1-2 was then
released after digestion with HindIII/XbaI and gel purified
(Qiagen #28406). For the supershift, 1 mg anti-FLAG antibody
(Sigma #F1804) was added to the reaction. Loading buffer (95%
Formamide, 10 mM EDTA, 0.1% xylene cyanol and 0.1%
bromophenol blue) was added to incubations prior to loading on
a 3.5%/8% non-denaturing TBE-polyacrylamide gel. The gel was
run in TBE buffer for 1 hour at 300 V and dried on Whatman
paper before exposing to Kodak biomax MS film (Kodak #829
4985). In vitro translated mLANA wt and mutants were detected by
Figure 5. mLANA DNA binding is essential for virus persistence and the dorsal positive patch exerts a role in the expansion of GC B
cells. (A) Amino acid substitutions in recombinant viruses (see also Figure S5). (B) Infection of BHK-21 cells at 0.01 p.f.u. per cell. Virus titres were
determined by plaque assay. (C) Lungs from infected mice were removed and infectious viruses were titrated by plaque assay. (D and E)
Quantification of latent infection in spleen by explant co-culture plaque assay (closed circles). Titres of infectious virus were determined in freeze/
thawed splenocyte suspensions (open circles). Each circle represents the titre of an individual mouse. The dashed line represents the limit of
detection of the assay. Mutant viruses are shown in panel D and revertant viruses in panel E. (F and G) Reciprocal frequencies of viral DNA-positive
cells in total splenocytes (F) or GC B cells (CD19+CD95hiGL7hi) (G) were determined by limiting dilution and real-time PCR. Data were obtained from
pools of five spleens per group. Bars represent the frequency of viral DNA-positive cells with 95% confidence intervals. (H) Identification of latently
infected cells in spleens by in situ hybridization. Representative splenic sections from each group of viruses are shown. All images are magnified
6200. Dark staining indicates cells positive for virally encoded miRNAs (see also Table 4).
doi:10.1371/journal.ppat.1003673.g005
Table 4. Reciprocal frequency of MuHV-4 infection in total splenocytes and GC B-cellsa.
Cell subpopulation Dpi Virus Reciprocal frequencyb of viral DNA positive cells
Total splenocytes 14 vWT 310 (198–707)
vmLANAH186D/K187E 17377 (11229–38406)
vmLANAK224A/K228A/K229A 2242 (1311–7712)
vmLANAK224E/K228E/K229E 3953 (2502–9373)
vmLANAK251A/K253A 499 (317–1170)
vmLANAK251E/K253E 448 (287–1019)
21 vWT 2243 (1405–5545)
vmLANAH186D/K187E 30949 (20094–67314)
vmLANAK224A/K228A/K229A 3322 (2148–7334)
vmLANAK224E/K228A/K229E 7985 (5134–17955)
vmLANAK251A/K253A 5979 (3653–16461)
vmLANAK251E/K253E 2296 (1442–5630)
50 vWT 4976 (3220–10952)
vmLANAH186D/K187E 24175 (15796–51478)
vmLANAK224A/K228A/K229A 28081 (18461–58638)
vmLANAK224E/K228E/K229E 16282 (10332–38380)
vmLANAK251A/K253A 12444 (8010–27880)
GC B-cellsc 14 vWT 6 (4–14)
vmLANAH186D/K187E 3079 (2006–6619)
vmLANAK224A/K228A/K229A 30 (20–59)
vmLANAK224E/K228E/K229E 284 (171–841)
vmLANAK251A/K253A 16 (10–39)
vmLANAK251E/K253E 6 (4–13)
aData were obtained from pools of at least five spleens. WT, wild type.
bFrequencies were calculated by limiting-dilution analysis with 95% confidence intervals (numbers in parentheses).
cThe purity of sorted cells was determined by fluorescence-activated cell sorting (FACS) analysis, and was always greater 95%.
doi:10.1371/journal.ppat.1003673.t004
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western blot. mLANA was resolved by 10% SDS-PAGE and after
transfer to nitrocellulose membrane, the protein detected using
monoclonal anti-mLANA (6A3) followed by HRP conjugated goat
anti-mouse secondary antibody (Southern Biotech #1031-05).
SPR and ITC analysis
SPR binding experiments were performed on a BIACORE
6100 instrument (GE Healthcare) at 25uC. Single stranded DNA
oligonucleotides, mLBS1 with an addition of five thymine’s in the
59 end as a spacer were annealed to its pair before injected over a
streptavidin-coated sensor chip (SA chip, GE Healthcare) at 1 nM
concentration at 10 ml min21 up to 590 RU. A flow cell was left
blank to allow background signal subtraction.
Purified recombinant mLANA124–272 protein dilution series
from higher to lower concentration were injected at a flow rate of
10–30 mL min21 for 3 min and the regeneration of the binding
surface was achieved by 4M NaCl. All the experiments were
performed in duplicates. Data were processed using BiaEvaluation
(GE Healthcare) and analyzed using SigmaPlot. The equilibrium
dissociation constant, KD, was determined by non-linear fitting of
the data using a 1:1 Langmuir isotherm.
We further examined mLANA-DNA binding using ITC.
Purified mLANA protein124–314 and mLBS1 DNA (without
biotin-TTTTT spacer) were dialyzed against 25 mM Na/K
phosphate pH 7.0, 150 mM NaCl, and 5% glycerol. ITC
titrations were performed with a MicroCal iTC200 Isothermal
Titration Calorimeter (MicroCal) at 25uC. Protein and DNA
absorbance were measured after dialysis by NanoDrop (Nano-
Drop Technologies) and their concentrations were determined
with their respective extinction coefficients. Twenty-five injections
of 1.5 ml each of 30 mM mLBS1 DNA were titrated into 8.5 mM
protein solution. Data were corrected for nonspecific heats and
analysed using MicroCal Origin 7.0 software using a one-site
binding model. The experiments were performed in triplicate and
showed similar results.
In vitro binding of mLANA and BRD4
BRD4, BRD4 1–470, 471–730, 731–1046, or 1047–1362 [41]
were in vitro translated and labelled with [35S]-methionine using
TNT Coupled Reticulocyte Lysate System (Promega). mLANA
K224A/K228A/K229A, mLANA K224E/K228E/K229E,
mLANA K251A/K253A or mLANA K251E/K253E each were
engineered to include three tandem C-terminal FLAG epitope tags
and were in vitro translated from pBluescript. GST, GST-N-
mLANA1–168 or GST-C-mLANA140–314 were expressed from
pGEX-2T. GST mLANA 124–272, GST mLANA 124–272
H186D/K187E, GST mLANA 124–272 K224A/K228A/
K229A, GST mLANA 124–272 K224E/K228E/K229E, GST
mLANA 124–272 K251A/K253A and GST mLANA 124–272
K251E/K253E fusion proteins were expressed from pET-49.
GST, GST mLANA or GST BRD4 [41] fusion proteins were
expressed in BL21 (DE3) bacteria and collected on Glutathione
Sepharose 4B (GE Healthcare) beads. GST fusion binding assays
were performed as described [41]. Proteins were resolved by SDS-
PAGE using 10% polyacrylamide, and transferred to nitrocellulose
membrane. 35S labelled BRD4 proteins were detected after
exposure to film, KSHV LANAD33-888 [58] was detected with
anti-T7NTag antibody (Novagen), and mLANA was detected with
anti-FLAG M2 antibody (Sigma).
Generation of recombinant viruses
MuHV-4 recombinant viruses were independently generated
by mutagenesis of the viral genome cloned as a bacterial artificial
chromosome (BAC) [59]. The point mutations were introduced
by PCR on the mLANA gene cloned into pCMV-Myc. pCMV-
Myc-mLANA was digested with HindIII and PciI or BstEII and
PciI to isolate the fragment harbouring the desired mutations, which
were inserted into the BamHI-G genomic clone. Recombinant
BamHI-G mutant fragments were subcloned into the BamHI site of
a pST76K-SR shuttle plasmid and transformed into an Escherichia
coli strain (DH10B) containing the wild-
type MuHV-4 BAC (pHA3). Following a multistep selection
procedure, recombinant BAC clones were identified by DNA
sequencing. To generate revertant viruses the wild type BamHI-G
pST76K-SR shuttle plasmid was transformed into DH10B cells
containing each of the mutant BAC genomes. The integrity of each
BAC was confirmed by restriction digestion with BamHI and
EcoRI. All viruses were reconstituted by transfection of BAC DNA
into BHK-21 cells using X-tremeGENE HP (Roche). The loxP-
flanked BAC cassette was removed by viral passage through NIH
Cre 3T3 cells and limiting dilution to obtain GFP-negative viruses.
Analysis of recombinant viruses
We performed five independent animal infections, which were
analyzed by five complementary experiments; ex vivo explant co-
culture assays to measure virus latency in total splenocytes, flow
cytometry coupled to limiting dilution and real-time PCR to
quantify the frequency of viral DNA-positive in total splenocytes
or to quantify GC B cells, and in situ hybridisation to identify
virally infected cells within the spleen. In situ hybridisation for
transcripts corresponding to the MHV-68-encoded miRNAs
permits the detection of latently infected cells in splenic sections.
Quantification of viral infection in GC B cells is highly relevant
since mLANA is selectively expressed in proliferating GC B cells
[25]. Revertant viruses were analysed at 14 days post-infection by
ex vivo explant co-culture assay by three independent animal
infections. C57BL/6 mice (Charles River, Spain) with 6–8 weeks
of age were intranasally inoculated with 104 p.f.u. in 20 ml of PBS
under isofluorane anaesthesia. At 3, 7, 14, 21 and 50 days post-
infection, lungs or spleens were removed and processed for
subsequent analysis. Infectious virus titers in freeze-thawed lung
homogenates were determined by suspension assay using BHK-
21 cells. Latent viruses were examined using explant co-cultures
of single-cell suspension splenocytes with BHK-21 cells. Plates
were incubated for 4 (suspension assay) or 5 days (co-culture
assay), fixed with 10% formal saline and counterstained with
toluidine blue. Viral plaques were counted with a plate
microscope. Frequencies of virus-genome-positive cells were
determined by limiting dilution combined with real-time PCR,
as described earlier [25]. Total splenocytes suspensions were
prepared from pools of five spleens. GC B-cell
(CD19+CD95hiGL7hi) populations were purified from pools of
five spleens using a BD FACSAria Flow Cytometer (BD
Biosciences). The purity of sorted populations was always
.95%, as analysed by flow cytometry. Real-time PCR reactions
were performed as reported [60]. To determine multistep growth
curves, BHK-21 cells were infected with MuHV-4 recombinant
viruses, at a low multiplicity of infection (0.01 p.f.u. per cell).
After 1 hour of virus adsorption, cells were washed in PBS and at
the indicated times post-infection virus titers were determined by
plaque assay. p values were determined using ordinary one-way
ANOVA (GraphPad Prism). In situ hybridisation was performed
on formalin-fixed, paraffin-embedded splenic sessions using
digoxigenin-labelled riboprobes, generated by T7 transcription
of pEH1.4 [61]. In situ hybridisation for transcripts corresponding
to the MHV-68-encoded miRNAs (encoded within pEH1.4)
permits the detection of latently infected cells in splenic sessions,
specifically within GC reactions.
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Accession codes
mLANA DNA AF105037; Uniprot accession numbers for
mLANA O41974 and kLANA Q76SB0; The atomic coordinates
and structure factors have been deposited in the Protein Data
Bank under accession number PDB ID: 4blg.
Supporting Information
Figure S1 Construct design of mLANA. (A) Schematic of
mLANA truncations. (B) list of primer sequences used for cloning
into the expression vector pET-49b(+); restriction enzyme sites are
shown in bold (BamHI used in forward primers and NotI in
reverse primers), extra bases to ensure the correct reading frame in
red and stop codons are underlined. (C) Coomassie blue stained
SDS-PAGE of GST-6XHis-mLANA constructs purified by Ni2+-
sepharose beads.
(TIF)
Figure S2 mLANA DBD homodimer analysis. (A) The
residues that constitute the hydrophobic core and hydrogen-
bonding network of the dimer interface are coloured by amino
acid group. The interactions are composed of 83 non-bonded
contacts (where the interaction distance is #3.9 A˚) with only 7
direct hydrogen bonds involved. The figure was generated by
PDBSUM. (B) Purified mLANA DBD truncations were analysed
by size exclusion chromatography. The majority of the mLANA
truncations elute as a dimer, however, the elution profile of
mLANA140–314 is consistent with a tetramer. (C) Biophysical
characterization of mLANA protein truncations, showing the
theoretical and calculated molecular weight (Mr) of each
truncation. The calculated oligomerization state and protein
stability profiles are also shown. Ve – elution volume, Kav -
partition coefficient.
(TIF)
Figure S3 Sequence analysis of MHV-68 and KSHV
LANA Binding Sites (LBS). KSHV LBS1 and LBS2 are
highlighted in blue and orange (which includes the 16 bp core)
and the putative MHV-68 DNA footprints underlined in green
and red [24]. Several potential mLANA LBS DNA sequences
tested for energy minimization and respective result values (z-score
in brackets). Energy minimization for 3D structures of mLANA-
DNA models was performed using YASARA.
(TIF)
Figure S4 Coomassie blue staining of BRD4 fusion
proteins. GST, GST-BRD4 471–594 or GST-BRD4 595–730
proteins used for binding mLANA. Similar amounts of protein
used in the mLANA binding assay are shown despite staining
differently with Ponceau S in Figure 4, panel E.
(TIF)
Figure S5 Sequence comparison of the ventral and
dorsal face of LANA, EBV EBNA1 and HPV6 E2 proteins.
(A) Table comparing the key residues of mLANA involved in DNA
interactions on the ventral face showing the equivalent residues in
kLANA, E2 and EBNA1 proteins. (B) Table comparing the key
residues that contribute to the contrasting electrostatic surfaces on
the dorsal face of LANA, EBNA1 and E2 proteins.
(TIF)
Figure S6 The mLANA dimer binds cooperatively to
mLBS1-2. (A) The elution profile of mLANA140–272 dimer from
size-exclusion chromatography (predicted size 31.8 kDa) in the
absence of DNA. (B) The elution profile of mLANA140–272 after
incubation with mLBS1, (predicted size of mLANA140–272 dimer-
mLBS1 complex 49.4 kDa). (C) The elution profile of mLANA140–
272 after incubation with mLBS1-2, (predicted size of mLANA140–
272-mLBS1-2 complex 92.8 kDa). Samples were analysed on a
Superdex 200 10/300 GL column. Peak fractions were analysed
by SDS-PAGE (4–20% gradient gel) and stained for both protein
(Coomassie blue) and mLBS DNA (Sybr Safe). SEC analysis
confirms the binding of one mLANA140–272 dimer to the mLBS1
site (estimated size 51.8 kDa, Ve 15.8 ml) and two mLANA140–272
dimers to the mLBS1-2 sites (estimated size 93.6 kDa, Ve 13.9 ml).
For panels B and C, the A280 nm signal indicating protein is
amplified due to the contribution of DNA in the complex, Ve is the
sample elution volume and M represents protein standards
(Supporting Information, Text S1).
(TIF)
Text S1 Supporting data including a supporting method
and supporting results.
(DOCX)
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